| Autor: |
Cabero‐Martínez, A., Bastos‐Oreiro, M., López‐García, A., Baile, M., Franch, M., Llacer‐Ferrandis, M. J., Izuzquiza, M., Jiménez‐Ubieto, A., Escoda, L., Nistal, S., González‐Barca, E., García‐Belmonte, D., Hernández‐Mohedo, F., Sánchez‐González, B., Martin‐Martitegui, X., Arguiñano, J. M., Ramirez‐Payer, A., Roldan‐Perez, A., Zeberio, I., Diaz‐Galvez, J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p816-818, 3p |
| Abstrakt: |
B Introduction: b Lymphoma patients may be especially vulnerable to COVID-19, due to the immune dysregulation caused by the lymphoma itself and the antitumor treatments. B Conclusions: b Our results confirm a high mortality in patients with lymphoma hospitalized before 2022 for COVID-19, especially in those >=70 years old, with cardiac comorbidities, heavily pretreated or with active lymphoma. With a median follow-up of 137 days (6-597), 118 patients have died (102 from COVID-19), with an estimated 90-day OS of 72% (95% CI 67%-76%) and 64% (95% CI 58%-69%) in the overall series and hospitalized patients, respectively. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text